ASX · M7T.AX
Mach7 Technologies Limited
A$0.26+A$0.01 (+2.0%)
Mach7 Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 62.77% below the high.
Loading market information…
ASX · MVP.AX · AUD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Medical Developments International Limited’s quoted price sits in the lower half of its reported 52-week range, 48.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Medical Developments International Limited’s forward annual dividend is A$0.04 per share, paid semi-annual. The forward yield is 10.36% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Medical Developments International Limited’s next earnings report is currently expected on Feb 25, 2027, with estimated earnings per share of A$0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medical Developments International Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divided into two primary segments: Pain Management and Respiratory care. Among its key offerings is Penthrox, a product specifically formulated for rapid pain relief in acute trauma and emergency situations. Within the respiratory segment, MDIL supplies equipment designed to assist individuals with conditions like asthma and chronic obstructive pulmonary disease (COPD). Additionally, its comprehensive portfolio features a diverse array of medical devices, encompassing items such as CPR face shields and masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, oxygen resuscitation kits, and various oxygen therapy and resuscitation apparatus. Established in 2003, the company maintains its headquarters in Scoresby, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| A$18.10M0.0% vs estimate |
| Q2 2024 | Feb 28, 2024 | -A$0.12-217.02% vs estimate | A$15.08M-24.59% vs estimate |
|---|
| Q4 2023 | Aug 30, 2023 | -A$0.10 | A$18.70M+16.88% vs estimate |
|---|
| Q2 2023 | Feb 23, 2023 | A$0.03 | A$13.93M-62.94% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.26+A$0.01 (+2.0%)
Mach7 Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 62.77% below the high.
A$0.18+A$0.00 (0.0%)
Singular Health Group Ltd’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
A$0.43+A$0.05 (+12.34%)
Cyclopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 66.47% below the high.
A$0.09-A$0.00 (-1.12%)
Amplia Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 68.0% below the high.
A$0.15A$0.00 (0.0%)
Next Science Limited’s quoted price sits in the upper half of its reported 52-week range, 6.45% below the high.
A$0.04-A$0.00 (-5.13%)
Micro-X Limited’s quoted price sits in the lower half of its reported 52-week range, 67.83% below the high.
A$0.08+A$0.01 (+8.57%)
PainChek Limited’s quoted price sits in the lower half of its reported 52-week range, 84.8% below the high.
